ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report)’s share price was up 0.3% during mid-day trading on Monday . The stock traded as high as $62.96 and last traded at $62.38. Approximately 35,751 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 37,731 shares. The stock had previously closed at $62.20.
ALPS Medical Breakthroughs ETF Stock Performance
The business’s 50-day moving average is $65.94 and its 200-day moving average is $58.75.
Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF
Large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of ALPS Medical Breakthroughs ETF by 63.1% in the 1st quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock worth $5,165,000 after purchasing an additional 38,193 shares in the last quarter. Moran Wealth Management LLC increased its position in ALPS Medical Breakthroughs ETF by 39.2% during the 1st quarter. Moran Wealth Management LLC now owns 29,348 shares of the company’s stock valued at $1,536,000 after buying an additional 8,264 shares in the last quarter. Sterling Investment Advisors Ltd. increased its position in ALPS Medical Breakthroughs ETF by 50.1% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 22,025 shares of the company’s stock valued at $1,153,000 after buying an additional 7,350 shares in the last quarter. Connors Investor Services Inc. purchased a new position in ALPS Medical Breakthroughs ETF during the fourth quarter valued at $338,000. Finally, Independent Financial Group LLC purchased a new position in ALPS Medical Breakthroughs ETF during the first quarter valued at $283,000.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Further Reading
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
